Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05349617 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years
A Phase 3 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 3
- Development phase
- 413
- Enrollment target
NCT05349617 is a Phase 3 study that has completed, run by Bavarian Nordic. The registered enrollment target is 413 participants.
The verdict
NCT05349617, a Phase 3 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 413 participants
- Enrollment target
Study Summary
The purpose of this phase 3, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity to PXVX0317 in adults ≥65 years of age.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CHIKV VLP/adjuvant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2022-05-12 |
| Est. Completion | 2023-08-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05349617
The ClinicalTrials.gov registry entry for NCT05349617 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 413 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05349617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05349617 about?
NCT05349617 is a clinical study titled "Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years". The purpose of this phase 3, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity to PXVX0317 in adults ≥65 years of age.
What is the current status of trial NCT05349617?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 413 participants. The study started on 2022-05-12. Estimated completion is 2023-08-08.
What interventions are being tested in trial NCT05349617?
The interventions under investigation include: Placebo (BIOLOGICAL), CHIKV VLP/adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT05349617?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.